Rituximab for Patients with Idiopathic Thrombocytopenic Purpura
Authors: Francisco Javier Peñalver, Jose Rafael Cabrera
Journal: Annals of Internal Medicine (2007)

Letters21 August 2007Rituximab for Patients with Idiopathic Thrombocytopenic PurpuraFrancisco Javier Peñalver, MD and Jose Rafael Cabrera, MD, PhDFrancisco Javier Peñalver, MDFrom Fundación Hospital Alcorcón, 28922, Alcorcón, Madrid, Spain, and Hospital Universitario Puerta de Hierro, 28035 Madrid, Spain.Search for more papers by this author and Jose Rafael Cabrera, MD, PhDFrom Fundación Hospital Alcorcón, 28922, Alcorcón, Madrid, Spain, and Hospital Universitario Puerta de Hierro, 28035 Madrid, Spain.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-4-200708210-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read Arnold and colleagues' systematic review (1) on the use of rituximab for idiopathic thrombocytopenic purpura (ITP) with great interest. The authors mentioned a study by our group (2) but had excluded it from their meta-analysis, claiming that our study “did not report original data.” We cannot agree with this statement, for our report certainly compiles original data, which were reported previously in abstract form only (3). Our study fulfills sufficient criteria for inclusion in the meta-analysis. Our retrospective, multicenter study assessed the therapeutic efficacy and toxicity of rituximab in 89 patients with chronic ITP that ...References1. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25-33. [PMID: 17200219] LinkGoogle Scholar2. Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85:400-6. [PMID: 16550390] CrossrefMedlineGoogle Scholar3. Cabrera JR, Peñalver FJ, Millan I, Jimenez-Yuste V, Almagro M, Alvarez-Larran A, et al. Mabthera (rituximab) in the treatment of 92 patients with refractory immune thrombocytopenic purpura. [Abstract]. Blood. 2004;104:Abstract 2074. Google Scholar4. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232-9. [PMID: 15059147] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Francisco Javier Peñalver, MD; Jose Rafael Cabrera, MD, PhDAffiliations: From Fundación Hospital Alcorcón, 28922, Alcorcón, Madrid, Spain, and Hospital Universitario Puerta de Hierro, 28035 Madrid, Spain.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSystematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura Donald M. Arnold , Francesco Dentali , Mark A. Crowther , Ralph M. Meyer , Richard J. Cook , Christopher Sigouin , Graeme A. Fraser , Wendy Lim , and John G. Kelton Rituximab for Patients with Idiopathic Thrombocytopenic Purpura Donald M. Arnold and Mark A. Crowther Metrics 21 August 2007Volume 147, Issue 4Page: 281KeywordsDeath ratesDrugsIdiopathic thrombocytopenic purpuraLymphomaProspective studiesRashesResearch designRetrospective studiesSystematic reviewsToxicity ePublished: 21 August 2007 Issue Published: 21 August 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...